Education
About Us
Working with TipRanks
Follow Us
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
NAMS Analyst Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NAMS Stock 12 Month Forecast
Average Price Target
$47.57
▲(33.59% Upside)
| Highest Price Target$60.00 | Average Price Target$47.57 | Lowest Price Target$37.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Goldman Sachs
$30→$37
Hold
3.90%
Upside
Reiterated
12/02/25
TD Cowen
―
Buy
―
Reiterated
11/11/25
RBC Capital
$44
Buy
23.56%
Upside
Reiterated
11/10/25
Piper Sandler
$37→$60
Buy
68.49%
Upside
Reiterated
11/10/25
H.C. Wainwright
$48→$52
Buy
46.03%
Upside
Reiterated
11/10/25
Stifel Nicolaus
$44
Buy
23.56%
Upside
Reiterated
11/09/25
Promising Outlook for NewAmsterdam Pharma: Buy Rating Supported by Favorable Market Trends and Competitive AdvantagesWe continue to think the PREVAIL will confirm a strong (>20%) and differentiated profile for obicetrapib, unlocking a large blockbuster opportunity. There continues to be investor focus on HORIZON/pelacarsen (1H26) as a potential incremental de-risker for PREVAIL. There's also some concern however that if it disappoints, it could read negatively onto NAMS given the hypothesized effect of Lp(a) in obicetrapib's early MACE data. As we think about it, we see basically two scenarios here: pelacarsen shows a >15% MACE benefit or its effect is more marginal (say +/- ~10%)--given the strength of data behind Lp(a), we'd be surprised if there was no effect at all.
Needham
$40→$46
Buy
29.18%
Upside
Reiterated
11/05/25
NewAmsterdam Pharma's Promising Developments and EU Approval Prospects Drive Buy Rating5:24 PM 2025 PRICE TARGET & ESTIMATE CHANGE Company N.V. (NAMS) RATING BUY PRICE TARGET $46.00 from $40.00 PREV CLOSE $36.53 52-WEEK RANGE $14.06 - $41.47 3Q25 Recap; Obi EU 2H26, PREVAIL Results in 2H26/1H27 NAMS reported 3Q25 financials and provided a corp update. The main development over 3Q25 was acceptance of the obicetrapib (obi) MAA that sets up potential EU approval in 2H26. Recall, Meraniri has obi's EU commercial rights, and NAMS is eligible for royalties ranging from low-double digits to mid-20s. Investor focus remains on the PREV AIL CVOT trial and whether it confirms the 1yr MACE reduction reported in the BROADWAY trial. PREV AIL is event-driven, and results are still expected in 2H26/1H27. We expect NAMS to update readout timelines in 1H26.
William Blair
―
Buy
―
Reiterated
11/05/25
Citi
$42→$50
Buy
40.41%
Upside
Reiterated
10/20/25
Wells Fargo
$45
Buy
26.37%
Upside
Initiated
08/25/25
Leerink Partners
$45→$44
Buy
23.56%
Upside
Reiterated
08/07/25
Scotiabank
$52
Buy
46.03%
Upside
Reiterated
08/07/25
Cantor Fitzgerald
$42
Buy
17.94%
Upside
Reiterated
07/30/25
Jefferies
$45
Buy
26.37%
Upside
Reiterated
06/11/25
Guggenheim
$35→$41
Buy
15.14%
Upside
Reiterated
03/03/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Goldman Sachs
$30→$37
Hold
3.90%
Upside
Reiterated
12/02/25
TD Cowen
―
Buy
―
Reiterated
11/11/25
RBC Capital
$44
Buy
23.56%
Upside
Reiterated
11/10/25
Piper Sandler
$37→$60
Buy
68.49%
Upside
Reiterated
11/10/25
H.C. Wainwright
$48→$52
Buy
46.03%
Upside
Reiterated
11/10/25
Stifel Nicolaus
$44
Buy
23.56%
Upside
Reiterated
11/09/25
Promising Outlook for NewAmsterdam Pharma: Buy Rating Supported by Favorable Market Trends and Competitive AdvantagesWe continue to think the PREVAIL will confirm a strong (>20%) and differentiated profile for obicetrapib, unlocking a large blockbuster opportunity. There continues to be investor focus on HORIZON/pelacarsen (1H26) as a potential incremental de-risker for PREVAIL. There's also some concern however that if it disappoints, it could read negatively onto NAMS given the hypothesized effect of Lp(a) in obicetrapib's early MACE data. As we think about it, we see basically two scenarios here: pelacarsen shows a >15% MACE benefit or its effect is more marginal (say +/- ~10%)--given the strength of data behind Lp(a), we'd be surprised if there was no effect at all.
Needham
$40→$46
Buy
29.18%
Upside
Reiterated
11/05/25
NewAmsterdam Pharma's Promising Developments and EU Approval Prospects Drive Buy Rating5:24 PM 2025 PRICE TARGET & ESTIMATE CHANGE Company N.V. (NAMS) RATING BUY PRICE TARGET $46.00 from $40.00 PREV CLOSE $36.53 52-WEEK RANGE $14.06 - $41.47 3Q25 Recap; Obi EU 2H26, PREVAIL Results in 2H26/1H27 NAMS reported 3Q25 financials and provided a corp update. The main development over 3Q25 was acceptance of the obicetrapib (obi) MAA that sets up potential EU approval in 2H26. Recall, Meraniri has obi's EU commercial rights, and NAMS is eligible for royalties ranging from low-double digits to mid-20s. Investor focus remains on the PREV AIL CVOT trial and whether it confirms the 1yr MACE reduction reported in the BROADWAY trial. PREV AIL is event-driven, and results are still expected in 2H26/1H27. We expect NAMS to update readout timelines in 1H26.
William Blair
―
Buy
―
Reiterated
11/05/25
Citi
$42→$50
Buy
40.41%
Upside
Reiterated
10/20/25
Wells Fargo
$45
Buy
26.37%
Upside
Initiated
08/25/25
Leerink Partners
$45→$44
Buy
23.56%
Upside
Reiterated
08/07/25
Scotiabank
$52
Buy
46.03%
Upside
Reiterated
08/07/25
Cantor Fitzgerald
$42
Buy
17.94%
Upside
Reiterated
07/30/25
Jefferies
$45
Buy
26.37%
Upside
Reiterated
06/11/25
Guggenheim
$35→$41
Buy
15.14%
Upside
Reiterated
03/03/25
Best Analysts Covering NewAmsterdam Pharma Company
1 Month
xxx
Success Rate
6/8 ratings generated profit
Average Return
+3.96%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +3.96% per trade.
3 Months
xxx
Success Rate
7/10 ratings generated profit
Average Return
+25.87%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +25.87% per trade.
1 Year
Success Rate
10/11 ratings generated profit
Average Return
+48.80%
reiterated a buy rating 4 months ago
Copying George Farmer's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +48.80% per trade.
2 Years
xxx
Success Rate
11/11 ratings generated profit
Average Return
+119.55%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +119.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NAMS Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
21
10
6
1
1
Buy
5
3
4
9
9
Hold
10
8
5
5
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
36
21
15
15
14
Each month's total comprises the sum of three months' worth of ratings.
NAMS Financial Forecast
NAMS Stock Forecast FAQ
What is NAMS’s average 12-month price target, according to analysts?
Based on analyst ratings, NewAmsterdam Pharma Company’s 12-month average price target is 47.57.
What is NAMS’s upside potential, based on the analysts’ average price target?
NewAmsterdam Pharma Company has 33.59% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NAMS a Buy, Sell or Hold?
NewAmsterdam Pharma Company has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
What is NewAmsterdam Pharma Company’s price target?
The average price target for NewAmsterdam Pharma Company is 47.57. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $37.00. The average price target represents 33.59% Increase from the current price of $35.61.
The highest analyst price target is $60.00 ,the lowest forecast is $37.00. The average price target represents 33.59% Increase from the current price of $35.61.
What do analysts say about NewAmsterdam Pharma Company?
NewAmsterdam Pharma Company’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of NAMS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.